This test is most useful if any of these apply to you.
Phenylalanine is one of the building blocks of protein. Your body uses it to make proteins and usually converts excess amounts into tyrosine. Some is broken down through other routes that produce phenylacetic acid, or PAA. Gut bacteria also make PAA from phenylalanine that reaches the colon.
Free PAA in urine is an exploratory marker of this chemistry. Its association with phenylketonuria is well documented, but its usefulness for assessing gut health, choosing a diet, or predicting future disease hasn't been established. There is no validated prevention target, and a personal trend doesn't by itself make the result clinically useful.
PAA can come from both human and bacterial metabolism. It also forms when your body breaks down phenylethylamine, which participates in nervous system signaling. Small human feeding and drug studies found that urinary PAA mainly reflected phenylalanine metabolism and was a poor measure of phenylethylamine activity in the brain.
Your liver and kidneys attach glutamine to much of the PAA produced. The resulting compound is phenylacetylglutamine, usually shortened to PAGln, and it is a major form in which this pathway's products leave in urine. This test measures free PAA. Its level depends on production, conversion into other compounds, kidney handling, and urine concentration, so it doesn't directly measure how much protein your gut bacteria ferment.
Phenylketonuria, or PKU, usually results from an inherited deficiency of the enzyme that converts phenylalanine into tyrosine. Phenylalanine accumulates and more enters routes that produce phenylacetic, phenyllactic, and phenylpyruvic acids. A classic study directly measured free urinary PAA and found large amounts in untreated PKU. Healthy infants and children with milder high blood phenylalanine generally excreted much less.
A more recent study compared 51 people with early-treated PKU with 51 controls and also found higher urinary PAA. It used a different technique to profile urine, so its numerical results aren't directly comparable with routine organic acid testing. Another small study found that urinary PAGln correlated with blood phenylalanine, but PAGln is a different molecule. Neither study established free urinary PAA as a substitute for blood phenylalanine monitoring.
Blood phenylalanine is the established measurement for newborn screening and treatment monitoring. A urine acid pattern can support a metabolic investigation, but a low or unremarkable PAA result doesn't exclude PKU or establish that it is well controlled.
Some small studies in the 1980s found lower urinary PAA in people with depression. Part of this research measured total urinary phenylacetate, including PAA released from attached compounds during sample processing. That is a different measurement from free PAA in this test.
The findings were inconsistent. One study found no difference between people with unipolar depression and controls, and its feeding and drug experiments challenged the idea that urinary PAA reflects brain phenylethylamine. Free urinary PAA hasn't been validated for diagnosing depression or selecting an antidepressant.
The heart research concerns PAGln in blood. A study involving more than 5,000 people linked higher plasma PAGln with cardiovascular disease and subsequent adverse events. Platelets are the blood components that help form clots. Experiments with human platelets found increased responsiveness to clotting signals, and animal experiments supported a role in clot formation.
| Who Was Studied | What Was Compared | What They Found |
|---|---|---|
| 631 people with a major heart attack and disease in several coronary arteries | Plasma PAGln above versus below the group's middle value | The higher group had about 2.8 times the rate of a combined outcome of death, heart attack, stroke, or heart failure after adjustment for other risk factors. |
| 73 people included in the follow-up analysis of a study of heart failure caused by coronary disease | Higher versus lower serum PAGln groups of nearly equal size | Over about nine months, the higher group had about 3.5 times the rate of cardiovascular death or heart failure hospitalization after adjustment for hemoglobin and a blood marker of heart strain. The small study produced an imprecise estimate. |
These were observational associations involving a different molecule in a different specimen. They don't establish a cardiovascular risk estimate for free urinary PAA, or show that lowering this urine result prevents heart disease.
A study of 262 people found higher serum PAGln in those with Crohn's disease. Crohn's disease causes inflammation in the digestive tract. Bacterial experiments supported a link to microbial phenylalanine breakdown. The mouse experiments used phenylacetylglycine, a related compound that predominates in rodents, and found worse chemically induced colitis. Those findings don't establish that free urinary PAA diagnoses bowel inflammation or identifies a treatment for it.
An unusual result can have several explanations. A pattern involving several phenylalanine-related acids may raise suspicion of altered phenylalanine metabolism. An isolated PAA value cannot distinguish increased bacterial production from changes in your body's processing or excretion. A low result doesn't establish low protein intake, a shortage of a brain chemical, or a healthy microbiome.
Evidence-backed interventions that affect your Phenylacetic Acid level
Phenylacetic Acid is best interpreted alongside these tests.
Phenylacetic Acid is included in these pre-built panels.
See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.
A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.
90 biomarkers